Physician
Danbury Hospital
Danbury Hospital was paid $123.87M by Medicaid between Jan 2018 and Dec 2024, across 525 billing codes. Its largest line is 99285, emergency room visit (most serious) — 19% of everything it billed.
33Billing provider infoDANBURY HOSPITAL
DANBURY, CT 06810
DANBURY, CT 06810
33aNPI1548293343assigned 07/08/2006
33bProvider typeGeneral Practice Physician
28Total paid$123.87M
24GClaims3,341,221
24DCodes billed525
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Practice Physician providers in Connecticut
Rank by total paid#1 of 24
Median peer was paid$566K
This provider vs. median219×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 415,846 | $17.58M | |
| 2019 | 505,535 | $18.22M | |
| 2020 | 411,511 | $13.41M | |
| 2021 | 476,449 | $17.60M | |
| 2022 | 512,290 | $19.34M | |
| 2023 | 528,982 | $19.33M | |
| 2024incomplete | 490,608 | $18.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 77,021 | 64,659 | $23.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 84,377 | 70,411 | $14.05M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.5% | 79,166 | 69,477 | $11.79M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.7% | 117,602 | 29,340 | $7.11M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.7% | 33,231 | 26,959 | $4.61M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.5% | 41,075 | 27,015 | $3.07M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.5% | 4,701 | 4,399 | $3.05M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.2% | 6,403 | 5,885 | $2.70M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 22,368 | 6,230 | $2.25M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.7% | 8,165 | 7,318 | $2.11M |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.6% | 2,816 | 2,643 | $2.02M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 10,808 | 9,335 | $2.00M |
513 more codes
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.4% | 26,595 | $1.76M |
| S9480 | Intensive outpatient psychiatric services, per diem | 1.2% | 12,124 | $1.52M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 24,769 | $1.51M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.2% | 7,429 | $1.51M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 13,438 | $1.44M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 10,621 | $1.28M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 10,323 | $1.10M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,702 | $1.05M |
| 93975 | <1% | 5,272 | $1.04M | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 24,439 | $1.03M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 8,110 | $1.01M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,703 | $962K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 1,545 | $916K |
| 97010 | <1% | 11,792 | $864K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 15,719 | $849K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 3,293 | $716K |
| 59025 | Fetal non-stress test | <1% | 5,569 | $714K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,873 | $709K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,556 | $704K |
| 97161 | <1% | 12,029 | $670K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,582 | $598K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 21,472 | $572K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 21,433 | $571K |
| 87507 | <1% | 2,445 | $560K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 48,990 | $558K |
| 86900 | <1% | 16,104 | $557K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,102 | $551K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 15,157 | $523K |
| 80053 | Comprehensive metabolic panel | <1% | 74,674 | $516K |
| 80061 | Lipid panel | <1% | 52,227 | $512K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,398 | $478K |
| 94060 | <1% | 2,781 | $470K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,183 | $466K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 575 | $461K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 54,156 | $454K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13,759 | $449K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 684 | $429K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 17,920 | $383K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 142,652 | $369K |
| 76641 | <1% | 3,903 | $358K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 625 | $342K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,690 | $341K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 19,512 | $334K |
| 93970 | <1% | 2,370 | $323K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14,571 | $309K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,108 | $284K |
| 76801 | <1% | 2,705 | $275K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 7,221 | $266K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,885 | $264K |
| 93971 | <1% | 3,557 | $260K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,058 | $258K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 38,205 | $255K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 266 | $254K |
| 76830 | Ultrasound, transvaginal | <1% | 2,675 | $250K |
| 86235 | <1% | 7,151 | $246K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,921 | $246K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14,751 | $230K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,392 | $229K |
| 96367 | <1% | 4,861 | $224K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,248 | $222K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,349 | $199K |
| 77065 | Tomosynthesis, mammo | <1% | 1,752 | $197K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 672 | $191K |
| 76770 | <1% | 1,823 | $187K | |
| 86480 | <1% | 4,507 | $181K | |
| 82947 | <1% | 75,622 | $179K | |
| 74183 | <1% | 1,004 | $178K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 127,445 | $163K |
| 77066 | Tomosynthesis, mammo | <1% | 1,369 | $161K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 624 | $158K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,025 | $154K |
| 76642 | <1% | 2,356 | $147K | |
| 93017 | <1% | 3,614 | $144K | |
| 20610 | <1% | 687 | $143K | |
| 76536 | <1% | 1,763 | $139K | |
| 97165 | <1% | 2,190 | $133K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,067 | $133K |
| 96415 | <1% | 2,393 | $128K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,290 | $127K |
| 86803 | <1% | 12,374 | $117K | |
| 86780 | <1% | 10,981 | $113K | |
| 97035 | <1% | 2,196 | $112K | |
| 81514 | <1% | 675 | $110K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,742 | $110K |
| 97116 | <1% | 5,955 | $104K | |
| 82728 | <1% | 10,761 | $101K | |
| 71250 | <1% | 1,701 | $100K | |
| 97162 | <1% | 2,315 | $99K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 33,524 | $98K |
| 82607 | <1% | 9,308 | $95K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 477 | $94K |
| 88142 | <1% | 7,131 | $80K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 740 | $79K |
| 44970 | <1% | 13 | $78K | |
| 84153 | <1% | 6,379 | $77K | |
| 77080 | <1% | 707 | $75K | |
| 84439 | <1% | 11,993 | $75K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 5,220 | $74K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 15,147 | $72K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 73 | $71K |
| 93880 | <1% | 793 | $69K | |
| 88342 | <1% | 2,449 | $69K | |
| 97113 | <1% | 2,086 | $68K | |
| 47562 | <1% | 15 | $68K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 37,063 | $67K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,024 | $67K |
| 96417 | <1% | 1,371 | $66K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,553 | $66K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 547 | $65K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 47 | $65K |
| 83970 | <1% | 3,034 | $64K | |
| 86618 | <1% | 7,602 | $62K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 291 | $61K |
| 87081 | <1% | 14,330 | $58K | |
| 85027 | <1% | 17,802 | $58K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,738 | $57K |
| 72100 | <1% | 2,872 | $55K | |
| 87536 | <1% | 1,216 | $54K | |
| 93225 | <1% | 953 | $51K | |
| 87340 | <1% | 8,533 | $50K | |
| 87510 | <1% | 3,652 | $50K | |
| 87480 | <1% | 3,654 | $50K | |
| 87660 | <1% | 3,654 | $50K | |
| 83550 | <1% | 8,046 | $48K | |
| 97597 | <1% | 524 | $47K | |
| 86617 | <1% | 4,395 | $47K | |
| 84403 | <1% | 2,266 | $45K | |
| 83540 | <1% | 9,667 | $43K | |
| 72141 | <1% | 246 | $43K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 27 | $42K |
| 92526 | <1% | 612 | $42K | |
| 80051 | <1% | 53,376 | $41K | |
| 86039 | <1% | 5,471 | $41K | |
| 82784 | <1% | 4,458 | $41K | |
| 82570 | <1% | 12,535 | $40K | |
| 36430 | <1% | 279 | $39K | |
| 70486 | <1% | 1,142 | $38K | |
| 86706 | <1% | 4,884 | $37K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,347 | $35K |
| 93296 | <1% | 2,162 | $34K | |
| 86140 | <1% | 12,322 | $34K | |
| 82746 | <1% | 3,487 | $33K | |
| 84481 | <1% | 2,653 | $32K | |
| 87186 | <1% | 9,095 | $32K | |
| 87077 | <1% | 9,411 | $32K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 16,461 | $31K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,349 | $30K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 428 | $30K |
| 95816 | <1% | 176 | $29K | |
| 88304 | <1% | 2,609 | $29K | |
| 82105 | <1% | 2,437 | $29K | |
| 86360 | <1% | 1,194 | $29K | |
| 96416 | <1% | 135 | $28K | |
| 84702 | <1% | 6,845 | $28K | |
| 80074 | <1% | 818 | $28K | |
| 82043 | <1% | 7,071 | $27K | |
| 86003 | <1% | 452 | $27K | |
| 86225 | <1% | 2,992 | $27K | |
| 83525 | <1% | 2,741 | $27K | |
| 73030 | <1% | 2,797 | $25K | |
| 93350 | <1% | 58 | $25K | |
| 74018 | <1% | 2,789 | $25K | |
| 86762 | <1% | 3,644 | $25K | |
| 73564 | <1% | 2,829 | $25K | |
| 81001 | <1% | 36,051 | $24K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 207 | $24K |
| 83516 | <1% | 2,810 | $23K | |
| 83655 | <1% | 2,373 | $23K | |
| 94726 | <1% | 1,823 | $23K | |
| 77336 | <1% | 277 | $23K | |
| 86160 | <1% | 1,517 | $22K | |
| 84146 | <1% | 1,447 | $21K | |
| 83001 | <1% | 1,414 | $21K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,435 | $20K |
| 86787 | <1% | 2,544 | $20K | |
| 83020 | <1% | 1,842 | $19K | |
| 84410 | <1% | 536 | $19K | |
| 86704 | <1% | 2,381 | $19K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 220 | $19K |
| 87338 | <1% | 1,639 | $19K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 370 | $18K |
| 82247 | <1% | 45,987 | $18K | |
| 83735 | <1% | 20,468 | $17K | |
| 86850 | <1% | 15,537 | $17K | |
| G0390 | Trauma response team associated with hospital critical care service | <1% | 32 | $17K |
| 87070 | <1% | 5,051 | $17K | |
| 70496 | <1% | 101 | $17K | |
| 77412 | <1% | 108 | $16K | |
| 76825 | <1% | 31 | $16K | |
| 80069 | <1% | 3,391 | $16K | |
| 94010 | <1% | 168 | $16K | |
| 83002 | <1% | 1,065 | $15K | |
| 85652 | <1% | 10,338 | $15K | |
| 77334 | <1% | 49 | $15K | |
| 82565 | <1% | 79,206 | $15K | |
| 85610 | <1% | 29,753 | $15K | |
| 96411 | <1% | 381 | $14K | |
| 86665 | <1% | 1,557 | $14K | |
| 83880 | <1% | 4,082 | $14K | |
| 87486 | <1% | 1,111 | $14K | |
| 87581 | <1% | 1,111 | $13K | |
| 88307 | <1% | 802 | $13K | |
| 81003 | <1% | 20,961 | $13K | |
| 86695 | <1% | 1,161 | $13K | |
| 73630 | <1% | 2,150 | $13K | |
| 73130 | <1% | 2,174 | $13K | |
| 86708 | <1% | 1,517 | $12K | |
| 73502 | <1% | 1,515 | $12K | |
| 73610 | <1% | 2,554 | $12K | |
| 88112 | <1% | 1,324 | $11K | |
| 86376 | <1% | 1,147 | $11K | |
| 85730 | <1% | 7,748 | $11K | |
| 83690 | <1% | 25,591 | $11K | |
| 82670 | <1% | 484 | $11K | |
| 82950 | <1% | 2,707 | $11K | |
| 86769 | <1% | 287 | $10K | |
| 93798 | <1% | 144 | $10K | |
| 86431 | <1% | 2,697 | $10K | |
| 84156 | <1% | 5,320 | $10K | |
| 86696 | <1% | 732 | $10K | |
| 87075 | <1% | 2,755 | $10K | |
| 80076 | <1% | 1,708 | $10K | |
| 80050 | General health panel | <1% | 341 | $9K |
| 73110 | <1% | 1,572 | $9K | |
| 87503 | <1% | 2,343 | $9K | |
| 82533 | <1% | 1,168 | $9K | |
| 10005 | <1% | 18 | $9K | |
| 86359 | <1% | 1,213 | $9K | |
| 87625 | <1% | 397 | $9K | |
| 84450 | <1% | 49,476 | $8K | |
| 82378 | <1% | 1,307 | $8K | |
| 96402 | <1% | 227 | $8K | |
| 86765 | <1% | 773 | $8K | |
| 82550 | <1% | 4,402 | $8K | |
| 84165 | <1% | 1,461 | $8K | |
| 86735 | <1% | 727 | $8K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,822 | $8K |
| 84703 | <1% | 14,152 | $8K | |
| 95806 | <1% | 61 | $7K | |
| 82150 | <1% | 6,682 | $7K | |
| 86200 | <1% | 792 | $7K | |
| 86364 | <1% | 797 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 219 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 30,025 | $7K |
| 10060 | <1% | 54 | $7K | |
| 0240U | <1% | 72 | $7K | |
| 83521 | <1% | 566 | $7K | |
| 73560 | <1% | 696 | $7K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 154 | $7K |
| 81511 | <1% | 77 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,321 | $6K |
| 83883 | <1% | 626 | $6K | |
| 86664 | <1% | 850 | $6K | |
| 84550 | <1% | 3,693 | $5K | |
| 29581 | <1% | 131 | $5K | |
| 82330 | <1% | 1,461 | $5K | |
| 83615 | <1% | 3,129 | $5K | |
| 43249 | <1% | 12 | $5K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 757 | $5K |
| 85651 | <1% | 2,393 | $5K | |
| 73562 | <1% | 274 | $5K | |
| 85380 | <1% | 4,873 | $5K | |
| 87631 | <1% | 1,059 | $5K | |
| 86901 | <1% | 16,027 | $5K | |
| 93978 | <1% | 53 | $5K | |
| 84075 | <1% | 45,516 | $4K | |
| 82977 | <1% | 5,784 | $4K | |
| 97014 | <1% | 107 | $4K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,012 | $4K |
| 88173 | <1% | 593 | $4K | |
| 84480 | <1% | 376 | $4K | |
| 86709 | <1% | 562 | $4K | |
| 84100 | <1% | 5,117 | $4K | |
| 85046 | <1% | 1,416 | $4K | |
| 84402 | <1% | 429 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 245 | $4K |
| 83993 | <1% | 251 | $4K | |
| G0378 | Hospital observation service, per hour | <1% | 7,256 | $4K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 58 | $4K |
| 74174 | <1% | 12 | $4K | |
| 87522 | Neg quan hep c or qual rna | <1% | 137 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 312 | $4K |
| 82951 | <1% | 307 | $3K | |
| 87634 | <1% | 57 | $3K | |
| 97760 | <1% | 78 | $3K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 513 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,363 | $3K |
| 82374 | <1% | 24,590 | $3K | |
| 82248 | <1% | 3,532 | $3K | |
| 77300 | <1% | 18 | $3K | |
| 86870 | <1% | 14 | $3K | |
| 73080 | <1% | 665 | $3K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 260 | $3K |
| 73140 | <1% | 766 | $3K | |
| 72070 | <1% | 96 | $2K | |
| 87205 | <1% | 2,262 | $2K | |
| 97166 | <1% | 38 | $2K | |
| 82652 | <1% | 74 | $2K | |
| 87209 | <1% | 261 | $2K | |
| 82040 | <1% | 1,601 | $2K | |
| 87040 | <1% | 4,180 | $2K | |
| 82310 | <1% | 5,775 | $2K | |
| 93270 | <1% | 117 | $2K | |
| 84144 | <1% | 119 | $2K | |
| 80164 | <1% | 483 | $2K | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 24 | $2K |
| 86146 | <1% | 106 | $2K | |
| 87177 | <1% | 274 | $2K | |
| 82435 | <1% | 24,694 | $2K | |
| 12001 | <1% | 1,173 | $2K | |
| 86334 | <1% | 133 | $2K | |
| 73221 | <1% | 12 | $2K | |
| 84300 | <1% | 511 | $1K | |
| 72170 | <1% | 598 | $1K | |
| 85007 | <1% | 1,644 | $1K | |
| 76377 | <1% | 6,233 | $1K | |
| 97022 | <1% | 24 | $1K | |
| 87529 | <1% | 80 | $1K | |
| 73590 | <1% | 430 | $1K | |
| 96376 | <1% | 8,701 | $1K | |
| 70498 | <1% | 119 | $1K | |
| 83721 | <1% | 353 | $1K | |
| 97533 | <1% | 61 | $1K | |
| 86308 | <1% | 660 | $989.71 | |
| 81025 | <1% | 8,553 | $983.01 | |
| 82077 | <1% | 7,629 | $967.09 | |
| 76882 | <1% | 19 | $966.04 | |
| 76820 | <1% | 282 | $948.22 | |
| 93923 | <1% | 12 | $946.43 | |
| 97164 | <1% | 13 | $944.13 | |
| 86800 | <1% | 87 | $943.62 | |
| 84520 | <1% | 78,448 | $942.26 | |
| 82627 | <1% | 49 | $934.12 | |
| 84425 | <1% | 55 | $899.14 | |
| 93298 | <1% | 94 | $860.94 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,433 | $829.20 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 975 | $813.59 |
| 86300 | <1% | 170 | $794.80 | |
| 84154 | <1% | 72 | $785.02 | |
| 84460 | <1% | 48,130 | $776.49 | |
| 82340 | <1% | 211 | $756.93 | |
| 86304 | <1% | 107 | $738.66 | |
| 76813 | <1% | 1,565 | $732.32 | |
| 84445 | <1% | 18 | $728.55 | |
| 83605 | <1% | 12,410 | $717.06 | |
| 83718 | <1% | 121 | $711.62 | |
| 74019 | <1% | 70 | $700.88 | |
| 87468 | <1% | 786 | $680.58 | |
| 84484 | <1% | 16,756 | $677.45 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 25 | $625.67 |
| 88300 | <1% | 130 | $598.88 | |
| 97763 | <1% | 19 | $498.96 | |
| 84132 | <1% | 25,084 | $494.52 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,422 | $494.00 |
| 86923 | <1% | 132 | $474.12 | |
| 86301 | <1% | 42 | $457.01 | |
| 90715 | <1% | 1,882 | $451.34 | |
| 85384 | <1% | 69 | $446.99 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,893 | $439.09 |
| 84155 | <1% | 345 | $416.41 | |
| 87469 | <1% | 769 | $410.00 | |
| 93280 | <1% | 34 | $405.15 | |
| 86255 | <1% | 40 | $404.91 | |
| 84466 | <1% | 42 | $402.27 | |
| 82465 | <1% | 123 | $381.00 | |
| 86036 | <1% | 33 | $353.36 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,566 | $343.19 |
| 93922 | <1% | 17 | $309.45 | |
| 82103 | <1% | 26 | $276.05 | |
| 86812 | <1% | 12 | $271.15 | |
| 83519 | <1% | 24 | $236.25 | |
| 84295 | <1% | 24,759 | $232.30 | |
| 85018 | <1% | 228 | $232.08 | |
| 84305 | <1% | 15 | $223.30 | |
| 90686 | <1% | 51 | $220.85 | |
| 84181 | <1% | 281 | $219.74 | |
| 94750 | <1% | 1,079 | $216.55 | |
| 82962 | <1% | 16,888 | $202.63 | |
| J3490 | Unclassified drugs | <1% | 39,140 | $198.85 |
| 85613 | <1% | 24 | $191.94 | |
| 82785 | <1% | 12 | $188.76 | |
| 82010 | <1% | 1,455 | $176.17 | |
| 36416 | <1% | 11,905 | $175.17 | |
| 83520 | <1% | 14 | $173.04 | |
| 86592 | <1% | 50 | $154.66 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 38 | $140.00 |
| 82800 | <1% | 1,281 | $134.66 | |
| 84478 | <1% | 132 | $129.64 | |
| 76870 | <1% | 230 | $129.34 | |
| 80177 | <1% | 12 | $113.94 | |
| 86705 | <1% | 12 | $112.50 | |
| 51701 | <1% | 128 | $91.65 | |
| 85014 | <1% | 68 | $85.88 | |
| 89051 | <1% | 52 | $84.16 | |
| 86060 | <1% | 14 | $83.64 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 998 | $83.00 |
| 73090 | <1% | 101 | $79.46 | |
| 12002 | <1% | 95 | $72.00 | |
| 73565 | <1% | 41 | $71.19 | |
| 82140 | <1% | 33 | $69.60 | |
| 80178 | <1% | 32 | $63.10 | |
| 99152 | <1% | 1,460 | $58.06 | |
| 85670 | <1% | 12 | $55.10 | |
| 82360 | <1% | 12 | $49.16 | |
| 12011 | <1% | 728 | $49.11 | |
| 81050 | <1% | 17 | $37.18 | |
| 82803 | <1% | 45 | $33.89 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,323 | $33.21 |
| 85060 | <1% | 35 | $32.20 | |
| 81002 | <1% | 1,442 | $31.72 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 85 | $24.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 6,684 | $22.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,018 | $21.41 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,105 | $18.33 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 21,048 | $14.57 |
| 51798 | <1% | 268 | $9.88 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 28,003 | $5.39 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,266 | $5.38 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 760 | $4.55 |
| 94729 | <1% | 3,125 | $3.89 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,819 | $3.81 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 609 | $3.74 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,875 | $3.60 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 531 | $2.66 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,251 | $2.19 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,212 | $2.18 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 448 | $2.17 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 677 | $1.24 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,149 | $0.36 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 165 | $0.35 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,355 | $0.29 |
| J1815 | Injection, insulin, per 5 units | <1% | 609 | $0.23 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,332 | $0.23 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 11,618 | $0.21 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 49 | $0.19 |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 82 | $0.17 |
| 93226 | 0% | 953 | $0.00 | |
| S0028 | Injection, famotidine, 20 mg | 0% | 615 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 2,516 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,213 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 851 | $0.00 |
| 80179 | 0% | 1,341 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 3,661 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,314 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 3,876 | $0.00 |
| 80143 | 0% | 1,427 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 2,169 | $0.00 |
| 93325 | 0% | 74 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 400 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 744 | $0.00 |
| 87641 | 0% | 14 | $0.00 | |
| 94727 | 0% | 17 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 203 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 220 | $0.00 |
| J2800 | Injection, methocarbamol, up to 10 ml | 0% | 185 | $0.00 |
| 36592 | 0% | 19 | $0.00 | |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 57 | $0.00 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0% | 102 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 325 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 504 | $0.00 |
| J9190 | Injection, fluorouracil, 500 mg | 0% | 436 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 140 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 16 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 41 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 44 | $0.00 |
| 99157 | 0% | 45 | $0.00 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 28 | $0.00 |
| 97803 | 0% | 19 | $0.00 | |
| 76942 | 0% | 32 | $0.00 | |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 26 | $0.00 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 58 | $0.00 |
| 76827 | 0% | 31 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 14 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 6,641 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 3,718 | $0.00 |
| C1769 | Guide wire | 0% | 2,222 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,318 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 153 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 796 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 1,732 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,097 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,714 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 20,225 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 952 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 934 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 452 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 2,790 | $0.00 |
| 88341 | 0% | 875 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 233 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 300 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 103 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 457 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,514 | $0.00 |
| 71101 | 0% | 75 | $0.00 | |
| 96368 | 0% | 77 | $0.00 | |
| 88141 | 0% | 245 | $0.00 | |
| 99156 | 0% | 108 | $0.00 | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 297 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 145 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 158 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 54 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 14 | $0.00 |
| Q3014 | Telehealth originating site facility fee | 0% | 33 | $0.00 |
| J9267 | Injection, paclitaxel, 1 mg | 0% | 19 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 59 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 100 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 81 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 32 | $0.00 |
| C1726 | Catheter, balloon dilatation, non-vascular | 0% | 27 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 74 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 38 | $0.00 |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 33 | $0.00 |
| 88311 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEBARBA, DANIEL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Norwalk Hospital Association | Norwalk, CT | $77.51M |
| Danbury Hospital | New Milford, CT | $15.34M |
| Nuvance Health Medical Practice, PC | Poughkeepsie, NY | $15.31M |
| Hudson Valley Cardiovascular Practice, PC | Poughkeepsie, NY | $2.15M |
| Norwalk Hospital Association | Norwalk, CT | $1.93M |
| Western Connecticut Health Network Affiliates, INC. | Danbury, CT | $321K |
| Health Quest Home Care, INC. (Certified) | Poughkeepsie, NY | $200K |
| Western Connecticut Health Network Affiliates, INC. | Ridgefield, CT | $76K |
| Norwalk Hospital Association | Norwalk, CT | $23K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.